Gilles Lambert is Professor in Cell Biology and Biochemistry at the University of La Réunion Medical School (France) and a group leader at Inserm UMR1188 DéTROI laboratory.

Pr. Lambert was awarded a PhD in Pathophysiology from the University of Paris in 1998. He specialized in lipidology, first as a post-doctoral fellow at the Molecular Disease Branch of the National Institutes of Health (Bethesda MD, USA) under the supervision of Dr. H Bryan Brewer Jr. and then as a senior research fellow at the Heart Research Institute (Sydney NSW, Australia) in the lipid research group led by Pr. Philip Barter.

In recent years, Pr. Lambert has conducted seminal research projects on PCSK9, a protein that targets the LDL receptor for intracellular degradation, and as such, the target of novel cholesterol lowering therapies: the PCSK9 inhibitors. He has for instance recently unravelled the specific role of PCSK9 in insulin producing beta-cells.

Pr Lambert has also investigated the cellular pathways by which PCSK9 modulates the circulating levels of lipoprotein (a), a highly atherogenic lipoprotein species. His current research goals are to elucidate the genetic and the metabolic determinants of elevated lipoprotein (a) and associated cardiovascular disease risk.

Over the years Pr. Lambert has received several competitive research grants in Australia and in France to study the cardiovascular benefits and potential side effects of PCSK9 inhibition as well as the cellular and metabolic pathways governing lipoprotein (a) concentrations.


PCSK9i: What have we learnt, what else needs clarification?89th EAS Congress 2021(Anti PCSK9ReviewCholesterolTreatmentHypolipidemic drugs)PCSK9 - From promise to clinical practiceEAS AC in Lipidology